Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Past Programs
Date Speakers(s) Program Topic
January 2016 Thomas Dubensky, Ph.D
Chief Scientific Office
Aduro Biotech
Development of Cyclic Dinucleotides as a Treatment and an Adjuvant for Cancer Therapy


February 2016 Lance Berman, M.D.
Senior Vice President and Chief Medical Officer
Relypsa
Leveraging Polymer Science to Advance the Treatment of Hyperkalemia


March 2016 Jane Lebkowski, Ph.D.
President of R&D and Chief Scientific Officer
Asterias Biotherapeutics
Leveraging Polymer Science to Advance the Treatment of Hyperkalemia


April 2016 Wendy Young, Ph.D.
Vice President of Discovery Chemistry
Genentech
Discovery of GDC-0853: A Highly Potent, Selective and Non-Covalent Btk Inhibitor


May 2016 Chris Ehrlich
Managing Director
Locust Walk Partners
Recent Trends in the Biopharma Financing and Licensing Market


June 2016 Peter Van Vlasselaer, Ph.D.
Founder, President and Chief Executive Officer
ARMO BioSciences
Developing Therapeutic Cytokines to Fight Cancer


July 2016 Robert McDowell, Ph.D
Senior Vice President of Drug Discovery
MyoKardia
MYK-461: A Direct Modulator of Cardiac Contractility for the Treatment of Hypertrophic Cardiomyopathy


August 2016 Ian McCaffery, Ph.D
Vice President, Translational Sciences
Corvus Pharmaceuticals
Novel Immune Therapies for Cancer--the Adenosine Pathway


September 2016 Jeff Zablocki, Ph.D.
Senior Director
Gilead Sciences
Discovery of a Late Sodium Current Inhibitor, a Phase II Agent with Pre-clinical Anti-Ischemic and Anti-Arrhythmic Properties


October 2016 Michael Kavanaugh, M.D
Chief Scientific Officer and Head of Research and Non-Clinical Development
CytomX Therapeutics
Probody Therapeutics Enable Safer and More Effective Oncology Therapies


November 2016 Nima Farzan
Chief Executive Officer & President
PaxVax
From Cholera to Zika: Development Pathways for Prophylactic Vaccines


December 2016 Christopher Peetz
Former Chief Financial Officer and Head of Corporate Development
Tobira Therapeutics
Improvement of Fibrosis in Non-Alcoholic Steatohepatitis (NASH) Patients; Clinical Development of a Potential Small Molecule Therapeutic


 Future Programs

Gold Sponsors

CDD
ChanTest
Fisher Clinical
ReImagine Science
PharmaLegacy
ClinCapture
HitGen
AltScience
Jubilant

Silver Sponsors

WAVSIP
Selvita
Applied

Location Sponsor

Pii
© BioSF.org ALL RIGHTS RESERVED BioScience Forum